Slide 1: Second Quarter 2021 Earnings Presentation
ANGIODYNAMICS Second Quarter 2021 Earnings Presentation January 7, 2021 1
Slide 2: Forward-Looking Statement
Forward-Looking Statement Notice Regarding Forward-LookingStatements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, ca
Slide 3: Corporate Developments and FY2021 Guidance
Corporate Developments FY2021 Guidance We continued our focused investment in our three key technology platforms: NanoKnife, AngioVac and Auryon. Within our Thrombus Management portfolio we are progressing toward the planned launch of a multi-purpose mechanical aspiration thrombectomy device in cale
Slide 4: Second Quarter FY2021 Highlights
Second Quarter FY2021 Highlights Financial Performance Product Family Sales Growth YOY Vascular Interventions and Therapies Q2 FY2021 YTD FY2021 Q2 FY2021 Q2 FY2020 $ in thousands (except per share data) Change AngioVac® 24% 34% Revenue $72,770 $70,003 4.0% Auryon NA NA Thrombolytic 4% (2%) Core Per
Slide 5: Second Quarter FY2021 Results (unaudited)
Second Quarter FY2021 Results (unaudited) $ in thousands (except per share data) Q2 FY2021 Q2 FY2020 Change YTD FY2021 YTD FY2020 Change Revenue $72,770 $70,003 4.0% $142,986 $136,045 5.1% Vascular Interventions and Therapies $33,900 $31,150 8.8% $63,757 $60,063 6.2% Vascular Access $23,930 $22,784
Slide 6: GAAP to Non-GAAP Reconciliation
GAAP to Non-GAAP Reconciliation 6
Slide 7: Reconciliation of GAAP to Non-GAAP Net Income (Loss) and EPS
Reconciliation of GAAP to Non- Reconciliation of Net Loss to GAAP Net Income (Loss) and EPS Adjusted EBITDA (1) Includes costs related to merger and acquisition activities, restructurings, and unusual items, including asset impairments and write-offs, certain litigation, and other items. (2) Deferre
Slide 8: Thrombus Management Portfolio Update
ANGIODYNAMICS Thrombus Management Portfolio Update 8
Slide 9: DVT, PE and VTE
Deep Vein Pulmonary Venous Thrombosis Embolism Thromboembolism DVT A blood clot that forms + PE A DVT breaks free from a vein wall = VTE DVT and PE are collectively in a deep vein, usually and travels to the lungs blocking referred to as VTE the leg, groin or arm some or all of the blood supply 208,
Slide 10: Thrombus Current Portfolio
THROMBUS CURRENT PORTFOLIO COMPLEX MANAGEMENT Right Heart AngioVac’s use is currently focused on the Right Heart, which is a $77M addressable market. Purpose Built Portfolio & Technology Planned Launch Calendar 2021 FUTURE PORTFOLIO DEEP VEIN RIGHT MODERATE THROMBOSIS Pulmonary HEART A multi-purpose
Slide 11: The AngioVac Difference
AngioVac Cannula The Saline Difference AngioVac The AngioVac System allows for the continuous Circuit aspiration of embolic material such as fresh, soft thrombi or vegetation from the venous system Utilizing a self-expanding, nitinol reinforced funnel tip Filter Simultaneously reinfusing the patient
Slide 12: Thrombus Management: The Next Portfolio
THROMBUS MANAGEMENT THE NEXT PORTFOLIO Planned Portfolio Additions & U.S. Addressable Markets Expansion INNOVATION A purpose-built, $1.3B1 2 innovative product leveraging the strengths of the AngioVac cannula technology with Multi-Purpose Mechanical Aspiration off-circuit manual aspiration control P
Slide 13: AngioDynamics Second Quarter 2021
ANGIODYNAMICS Second Quarter 2021 Earnings Presentation January 7, 2021 13